|
Case
|
Age (years)
|
Sex
|
Post-mortem delay (h)
|
NIA-AA staging (AD neuropathologic change)
|
|---|
|
Normal
|
|
H169
|
81
|
Male
|
24
|
A2 B0 C1 (none)
|
|
H180
|
73
|
Male
|
33
|
A2 B0 C1 (none)
|
|
H187
|
98
|
Female
|
15
|
A2 B2 C1 (intermediate)
|
|
H191
|
77
|
Male
|
25
|
A0 B0 C0 (none)
|
|
H196
|
85
|
Male
|
15
|
A1 B0 C0 (none)
|
|
H229
|
88
|
Female
|
17
|
A2 B1 C2 (low)
|
|
H243
|
77
|
Female
|
13
|
A0 B0 C0 (none)
|
|
H246
|
89
|
Male
|
17
|
A0 B1 C0 (none)
|
|
Mean
|
83.5 ± 9.1
|
–
|
19.3 ± 6.5
|
–
|
|
AD
|
|
AZ99
|
94
|
Female
|
8.5
|
A3 B3 C2 (high)
|
|
AZ102
|
84
|
Female
|
14.5
|
A3 B2 C2 (intermediate)
|
|
AZ107
|
86
|
Male
|
N/A
|
A2 B3 C1 (intermediate)
|
|
AZ108
|
94
|
Female
|
11.5
|
A3 B3 C2 (high)
|
|
AZ109
|
90
|
Female
|
31
|
A3 B2 C1 (intermediate)
|
|
AZ110
|
86
|
Female
|
15
|
A3 B3 C2 (high)
|
|
AZ113
|
77
|
Male
|
3.5
|
A3 B3 C2 (high)
|
|
AZ119
|
89
|
Male
|
5
|
A3 B2 C2 (intermediate)
|
|
Mean
|
87.5 ± 5.6
|
–
|
12.7 ± 9.2
|
–
|
